Cargando…

Evaluation of a novel CD20-targeted IL-15 immunotherapeutic with potent activity against B cell lymphoma

Detalles Bibliográficos
Autores principales:	Liu, Bai, Kong, Lin, Marcus, Warren D, Chen, Xiaoyue, Han, Kaiping, Rhode, Peter R, Wong, Hing C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288423/ http://dx.doi.org/10.1186/2051-1426-2-S3-P122

Ejemplares similares

The IL-15 superagonist ALT-803 enhances anti-CD20 antibody-directed NK cell ADCC and in vivo clearance of B cell lymphomas
por: Rosario, Maximillian, et al.
Publicado: (2014)

Novel antitumor mechanism-of-action of an IL-2 fusion protein mediated by tumor associated macrophage repolarization and innate-like CD8+ memory T cells
por: Xu, Wenxin, et al.
Publicado: (2014)

Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syngenic mouse melanoma model
por: Chen, Xiaoyue, et al.
Publicado: (2015)

Enhanced efficacy of IL-15-based ALT-803 superagonist complex in combination with immune checkpoint inhibitors in hematologic and metastatic mouse tumor models
por: Xu, Wenxin, et al.
Publicado: (2014)

Enhanced efficacy of ALT-803, an IL-15-based superagonist complex, in combination with immune checkpoint inhibitors in an orthotopic muscle invasive bladder tumor model in mice
por: Xu, Wenxin, et al.
Publicado: (2015)

CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
por: Margolin, Kim, et al.
Publicado: (2014)

Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice
por: Johnson, Christopher B, et al.
Publicado: (2014)

ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors
por: Orentas, Rimas J, et al.
Publicado: (2013)

IL15N72D superagonist/IL15Rα-Fc fusion complex (ALT-803) exhibits anti-metastatic activity in murine breast tumor model
por: Kim, Peter S, et al.
Publicado: (2015)

Immunotherapeutic potential of varicella vaccine in smoldering and cutaneous adult T-cell leukemia/lymphoma
por: Amano, M, et al.
Publicado: (2014)

Leukemia/lymphoma development in IL-15-deficient TCR-transgenic mice
por: Dubois, Sigrid, et al.
Publicado: (2015)

CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells
por: Morishima, Chihiro, et al.
Publicado: (2015)

Selective costimulation by IL-15R/IL-15, but not IL-2R/IL-2, allows the induction of high numbers of tumor-specific CD8+ T cells by human dendritic cells matured in conditions of acute inflammation
por: Hansen, Morten, et al.
Publicado: (2015)

Electrotransfer of IL-15/IL-15Rα complex for the treatment of established melanoma
por: Shirley, Shawna, et al.
Publicado: (2015)

Interleukin-15 (IL-15) and IL-15 receptor alpha fusion protein enhances antitumor activity of myxoma virus
por: Tosic, Vesna, et al.
Publicado: (2013)

The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity
por: Wong, Hing C, et al.
Publicado: (2013)

P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic
por: Lykopoulos, K, et al.
Publicado: (2014)

Systemic delivery of liposome-anchored anti-CD137 and IL2-Fc prevents lethal toxicity and elicits potent antitumor immunity
por: Zhang, Yuan, et al.
Publicado: (2015)

IL-2, IL-15 and IL-21 expand T cells for targeted adoptive therapy
por: Liu, Zhenjiang, et al.
Publicado: (2015)

IL-15 and its role in rheumatoid arthritis
por: Kurowska-Stolarska, M, et al.
Publicado: (2003)

IL-15 is an inflammatory mediator in the tumor microenvironment
por: Anthony, Scott M, et al.
Publicado: (2015)

A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes
por: Slingluff, Craig L, et al.
Publicado: (2014)

Transpositional immunity: immunotherapeutical approach against bovine leukemia virus
por: Roa-Castellanos, RA
Publicado: (2009)

Identification of potential immunotherapeutic targets in antigen presentation and costimulation networks
por: Spaapen, Robbert, et al.
Publicado: (2014)

CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells
por: Morishima, Chihiro, et al.
Publicado: (2014)

P16-30. Induction of Tim-3 expression by the common gamma-chain cytokines IL-2, IL-7, IL-15 and IL-21
por: Jones, BR, et al.
Publicado: (2009)

IMM-101, an immunotherapeutic agent in clinical development as an adjunctive treatment for pancreatic cancer
por: Bilyard, Hilary, et al.
Publicado: (2014)

Immunotherapeutic targeting of HSP90 client proteins in BRAF-inhibitor resistant melanoma
por: Fecek, Ronald J, et al.
Publicado: (2015)

Intratumoral IL-15 potentiates radiation-induced anti-tumor immunity
por: Pilones, Karsten, et al.
Publicado: (2015)

Extremely potent immunotherapeutic activity of a STING agonist in the B16 melanoma model in vivo
por: Corrales, Leticia, et al.
Publicado: (2013)

Kaposi sarcoma herpesvirus (KSHV)-associated lymphomas are associated with markedly elevated serum IL-10, elevated IL-6, IL-17 and circulating KSHV
por: Uldrick, Thomas S, et al.
Publicado: (2012)

A role for IL-7 in regulating CD4(+)CD25(high )regulatory T cells
por: Lawson, CA, et al.
Publicado: (2005)

Immunomodulatory activity of SGI-110: a basis for novel chemo-immunotherapeutic combinations in cancer treatment
por: Covre, Alessia, et al.
Publicado: (2013)

P15-15. Advocates' perspectives on community engagement in the HVTN 505
por: Warren, M, et al.
Publicado: (2009)

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
por: Kim, Peter S., et al.
Publicado: (2016)

CD4 T cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T cell responses resulting in potent antitumor effects
por: Cho, Hyun-Il, et al.
Publicado: (2014)

Induction of potent systemic anti-melanoma immunity through intratumoral CD40 activation and checkpoint blockade
por: Singh, Manisha, et al.
Publicado: (2015)

The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities
por: Bjorck, Pia, et al.
Publicado: (2015)

Pharmacological inactivation of PI3Kδ in the tumor microenvironment enhances efficacy of other immunotherapeutic agents
por: Wang, Liang-Chuan S, et al.
Publicado: (2015)

The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
por: Tsang, Kwong Y, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qf9ji1kq2dchc22ef1s4ongksb